Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis) : an open-label, randomised, phase 3 trial
- Submitting institution
-
The University of Warwick
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 7812
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(15)70137-3
- Title of journal
- The Lancet Oncology
- Article number
- -
- First page
- 656
- Volume
- 16
- Issue
- 6
- ISSN
- 1470-2045
- Open access status
- Out of scope for open access requirements
- Month of publication
- June
- Year of publication
- 2015
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
20
- Research group(s)
-
-
- Citation count
- 76
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The author made a substantial contribution to the conception and design of the study and to the organisation of of the conduct of the study and to analysis and interpretation of study data. The author helped draft the output and helped critique the output for important intellectual content.
- Non-English
- No
- English abstract
- -
